[CATB] Catabasis Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.75 Change: -0.1 (-2.6%)
Ext. hours: Change: 0 (0%)

chart CATB

Refresh chart

Strongest Trends Summary For CATB

CATB is in the medium-term down -23% below S&P in 3 months and down -33% below S&P in 4 months. In the long-term up 332% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities16.89 M Cash From Investing Activities-30 K Cash From Operating Activities-7.23 M Gross Profit
Net Profit-6.5 M Operating Profit-6.36 M Total Assets26.73 M Total Current Assets24.85 M
Total Current Liabilities4.99 M Total Debt9.66 M Total Liabilities13.45 M Total Revenue
Technical Data
High 52 week8.72 Low 52 week0.62 Last close6.56 Last change-0.76%
RSI36.39 Average true range0.32 Beta1.06 Volume118.47 K
Simple moving average 20 days-6.28% Simple moving average 50 days-6.04% Simple moving average 200 days6.65%
Performance Data
Performance Week-5% Performance Month-13.68% Performance Quart47.09% Performance Half-3.53%
Performance Year302.45% Performance Year-to-date50.11% Volatility daily2.28% Volatility weekly5.1%
Volatility monthly10.44% Volatility yearly36.18% Relative Volume481.52% Average Volume82.7 K
New High New Low

News

2019-11-08 00:27:33 | Edited Transcript of CATB earnings conference call or presentation 7-Nov-19 1:30pm GMT

2019-11-07 08:05:00 | Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress

2019-10-24 08:00:00 | Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th

2019-10-19 09:26:15 | Catabasis Pharmaceuticals, Inc. NASDAQ:CATB: When Will It Breakeven?

2019-10-18 08:00:00 | Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting

2019-10-05 08:00:00 | Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy

2019-09-30 16:05:00 | Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment

2019-09-27 08:00:00 | Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society

2019-09-26 08:00:00 | Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy

2019-09-25 08:00:00 | Catabasis Pharmaceuticals Names Andrew A. Komjathy Chief Commercial Officer

2019-09-19 10:13:59 | How Much Of Catabasis Pharmaceuticals, Inc. NASDAQ:CATB Do Institutions Own?

2019-08-20 10:58:43 | Investors Who Bought Catabasis Pharmaceuticals NASDAQ:CATB Shares Three Years Ago Are Now Down 87%

2019-08-09 17:04:55 | Edited Transcript of CATB earnings conference call or presentation 8-Aug-19 12:30pm GMT

2019-08-08 08:05:00 | Catabasis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Reviews Business Progress

2019-08-07 08:00:00 | Catabasis Pharmaceuticals Appoints Hugh M. Cole to its Board of Directors

2019-08-06 08:00:00 | Catabasis Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

2019-07-25 08:30:00 | Catabasis Pharmaceuticals to Report Second Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, August 8th

2019-07-15 15:08:07 | Does Catabasis Pharmaceuticals, Inc.'s NASDAQ:CATB CEO Pay Reflect Performance?

2019-06-27 08:00:00 | Catabasis Pharmaceuticals Provides Update on Global Phase 3 PolarisDMD Trial for Edasalonexent at Parent Project Muscular Dystrophy 25th Annual Conference

2019-06-21 09:45:00 | Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy

2019-06-18 08:00:00 | Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference

2019-06-07 09:24:01 | Vertex Expands Collaboration With CRISPR, Acquires Exonics

2019-05-15 08:38:17 | SV Life Sciences Advisers, LLC Buys Catabasis Pharmaceuticals Inc, Sells KalVista ...

2019-05-14 14:20:57 | Edited Transcript of CATB earnings conference call or presentation 14-May-19 12:30pm GMT

2019-05-14 08:05:00 | Catabasis Pharmaceuticals Reports First Quarter 2019 Financial Results and Reviews Business Progress

2019-05-02 08:00:00 | Catabasis Pharmaceuticals to Present Data from the MoveDMD® trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 71st Annual Meeting

2019-04-30 08:00:00 | Catabasis Pharmaceuticals to Report First Quarter 2019 Financial Results and Recent Corporate Developments on Tuesday, May 14th

2019-04-26 15:26:02 | Should You Be Concerned About Catabasis Pharmaceuticals, Inc.'s NASDAQ:CATB Historical Volatility?

2019-04-12 11:34:03 | Top Ranked Momentum Stocks to Buy for April 12th

2019-04-01 08:00:00 | Catabasis Pharmaceuticals to Present at Upcoming Neuromuscular Translational Research Conference and MDA Clinical and Scientific Conference

2019-03-26 12:11:04 | Proteostasis Plunges on Weak Data From Cystic Fibrosis Study

2019-03-26 08:07:12 | Will Catabasis Pharmaceuticals Continue to Surge Higher?

2019-03-19 12:26:04 | Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight

2019-03-18 09:02:01 | Rising P/E an Overlooked Criterion: 5 Top Stocks

2019-03-14 18:09:10 | Edited Transcript of CATB earnings conference call or presentation 14-Mar-19 12:30pm GMT

2019-03-14 08:30:12 | Catabasis CATB Beats Earnings in Q4, Revenues Nil

2019-03-14 08:05:00 | Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Reviews Business Progress

2019-03-13 08:00:00 | Catabasis Pharmaceuticals to Present at Oppenheimer’s 29th Annual Healthcare Conference

2019-03-08 09:54:02 | Townsquare TSQ to Report Q4 Earnings: What's in the Cards?

2019-03-07 08:57:01 | Athersys ATHX Q4 Earnings: What's in Store for the Stock?

2019-03-07 08:51:01 | Is a Beat in Store for Catabasis CATB This Earnings Season?

2019-03-06 13:56:33 | Investors Who Bought Catabasis Pharmaceuticals Shares Three Years Ago Are Now Down 93%

2019-02-28 08:00:00 | Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Developments on Thursday, March 14

2019-02-19 08:00:00 | Catabasis Pharmaceuticals Presents Data Supporting Edasalonexent as a Potential Foundational Treatment for Duchenne Muscular Dystrophy

2019-02-14 08:00:00 | Catabasis Pharmaceuticals Appoints Joanne T. Beck to its Board of Directors

2019-02-06 09:00:00 | Catabasis Pharmaceuticals Announces Pricing of $20 Million Underwritten Public Offering

2019-02-06 08:23:47 | The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

2019-02-05 16:01:00 | Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering

2019-01-29 07:55:00 | New Research: Key Drivers of Growth for Tiffany, CarMax, Cars, RPC, Cleveland-Cliffs, and Catabasis Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

2019-01-15 11:10:39 | Is Catabasis Pharmaceuticals, Inc.’s NASDAQ:CATB CEO Overpaid Relative To Its Peers?